|
1
|
Shin A, Kim KZ, Jung KW, Park S, Won YJ,
Kim J, Kim DY and Oh JH: Increasing trend of colorectal cancer
incidence in Korea, 1999–2009. Cancer Res Treat. 44:219–226. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Colussi D, Brandi G, Bazzoli F and
Ricciardiello L: Molecular pathways involved in colorectal cancer:
Implications for disease behavior and prevention. Int J Mol Sci.
14:16365–16385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Di Caro G, Marchesi F, Laghi L and Grizzi
F: Immune cells: Plastic players along colorectal cancer
progression. J Cell Mol Med. 17:1088–1095. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ogino S, Galon J, Fuchs CS and Dranoff G:
Cancer immunology-analysis of host and tumor factors for
personalized medicine. Nat Rev Clin Oncol. 8:711–719. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zaanan A, Fléjou JF, Emile JF, Des GG,
Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C,
Rougier P, et al: Defective mismatch repair status as a prognostic
biomarker of disease-free survival in stage III colon cancer
patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer
Res. 17:7470–7478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sinicrope FA, Shi Q, Smyrk TC, Thibodeau
SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M,
Goldberg RM, et al: Molecular markers identify subtypes of stage
III colon cancer associated with patient outcomes.
Gastroenterology. 148:88–99. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galon J, Mlecnik B, Bindea G, Angell HK,
Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et
al: Towards the introduction of the ‘Immunoscore’ in the
classification of malignant tumours. J Pathol. 232:199–209. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mlecnik B, Bindea G, Angell HK, Maby P,
Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M,
Fredriksen T, et al: Integrative analyses of colorectal cancer show
immunoscore is a stronger predictor of patient survival than
microsatellite instability. Immunity. 44:698–711. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ostrand-Rosenberg S, Horn LA and Haile ST:
The programmed death-1 immune-suppressive pathway: Barrier to
antitumor immunity. J Immunol. 193:3835–3841. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hirano F, Kaneko K, Tamura H, Dong H, Wang
S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, et al: Blockade of
B7-H1 and PD-1 by monoclonal antibodies potentiates cancer
therapeutic immunity. Cancer Res. 65:1089–1096. 2005.PubMed/NCBI
|
|
14
|
Konishi J, Yamazaki K, Azuma M, Kinoshita
I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small
cell lung cancer cells and its relationship with tumor-infiltrating
lymphocytes and their PD-1 expression. Clin Cancer Res.
10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ohigashi Y, Sho M, Yamada Y, Tsurui Y,
Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al:
Clinical significance of programmed death-1 ligand-1 and programmed
death-1 ligand-2 expression in human esophageal cancer. Clin Cancer
Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thompson RH, Gillett MD, Cheville JC,
Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen
L, et al: Costimulatory B7-H1 in renal cell carcinoma patients:
Indicator of tumor aggressiveness and potential therapeutic target.
Proc Natl Acad Sci USA. 101:17174–17179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamanishi J, Mandai M, Iwasaki M, Okazaki
T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N,
et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+
T lymphocytes are prognostic factors of human ovarian cancer. Proc
Natl Acad Sci USA. 104:3360–3365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sabatier R, Finetti P, Mamessier E,
Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D and
Bertucci F: Prognostic and predictive value of PDL1 expression in
breast cancer. Oncotarget. 6:5449–5464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hino R, Kabashima K, Kato Y, Yagi H,
Nakamura M, Honjo T, Okazaki T and Tokura Y: Tumor cell expression
of programmed cell death-1 ligand 1 is a prognostic factor for
malignant melanoma. Cancer. 116:1757–1766. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu P, Wu D, Li L, Chai Y and Huang J:
PD-L1 and survival in solid tumors: A meta-analysis. PLoS One.
10:e01314032015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu Z, Jin Z, Zhang M, Tang Y, Yang G,
Yuan X, Yao J and Sun D: Prognostic value of programmed
death-ligand 1 in sarcoma: A meta-analysis. Oncotarget.
8:59570–59580. 2017.PubMed/NCBI
|
|
23
|
Droeser RA, Hirt C, Viehl CT, Frey DM,
Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A,
Rosso R, et al: Clinical impact of programmed cell death ligand 1
expression in colorectal cancer. Eur J Cancer. 49:2233–2242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee LH, Cavalcanti MS, Segal NH, Hechtman
JF, Weiser MR, Smith JJ, Garcia-Aguilar J, Sadot E, Ntiamoah P,
Markowitz AJ, et al: Patterns and prognostic relevance of PD-1 and
PD-L1 expression in colorectal carcinoma. Mod Pathol. 29:1433–1442.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saigusa S, Toiyama Y, Tanaka K, Inoue Y,
Mori K, Ide S, Imaoka H, Kawamura M, Mohri Y and Kusunoki M:
Implication of programmed cell death ligand 1 expression in tumor
recurrence and prognosis in rectal cancer with neoadjuvant
chemoradiotherapy. Int J Clin Oncol. 21:946–952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dunne PD, McArt DG, O'Reilly PG, Coleman
HG, Allen WL, Loughrey M, Van Schaeybroeck S, McDade S,
Salto-Tellez M, Longley DB, et al: Immune-derived PD-L1 gene
expression defines a subgroup of stage II/III colorectal cancer
patients with favorable prognosis who may be harmed by adjuvant
chemotherapy. Cancer Immunol Res. 4:582–591. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koganemaru S, Inoshita N, Miura Y, Miyama
Y, Fukui Y, Ozaki Y, Tomizawa K, Hanaoka Y, Toda S, Suyama K, et
al: Prognostic value of programmed death-ligand 1 expression in
patients with stage III colorectal cancer. Cancer Sci. 108:853–858.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen JK, Cote GM, Choy E, Yang P, Harmon
D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, et al:
Programmed cell death ligand 1 expression in osteosarcoma. Cancer
Immunol Res. 2:690–698. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng
P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et
al: Blockade of B7-H1 improves myeloid dendritic cell-mediated
antitumor immunity. Nature Med. 9:562–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song M, Chen D, Lu B, Wang C, Zhang J,
Huang L, Wang X, Timmons CL, Hu J, Liu B, et al: PTEN loss
increases PD-L1 protein expression and affects the correlation
between PD-L1 expression and clinical parameters in colorectal
cancer. PLoS One. 8:e658212013. View Article : Google Scholar : PubMed/NCBI
|
